SINPHAR — Investor Presentation 2024

Dec 19, 2024

==> picture [258 x 100] intentionally omitted <==

==> picture [149 x 100] intentionally omitted <==

==> picture [150 x 100] intentionally omitted <==

==> picture [165 x 100] intentionally omitted <==

SINPHAR PHARMACEUTICAL CO., LTD.

2024 Investor Conference

Chairman Chih Wen Lee General Manager: Yu Liang Pei Chief Financial Officer: Chih Hsiao Chen December 19, 2024

==> picture [219 x 88] intentionally omitted <==

==> picture [169 x 88] intentionally omitted <==

==> picture [155 x 87] intentionally omitted <==

==> picture [179 x 87] intentionally omitted <==

1

Disclaimer

• 本簡報是建立於本公司從各項來源所取得之資訊。有些 訊可能受未來不確定性因素影響，致使與原先本公司對 於未來前景的說明迥異。未來若有變更或調整時，請以 公開資訊觀測站公告資訊為依據。

• 所涉產業為法規高度規範與高度專業領域，提醒投資人 須審慎投資。

• This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cause actual results to differ materially from those statements. Therefore, please refer to the information on MOPS website as the main basis if any adjustment has been made. (http://mops.twse.com.tw/mops/web/index)

• The industries involved are highly regulated and highly specialized fields, and investors are reminded to invest prudently.

2

Contents

1. Outlook 2. Operations Development

3 ~~. Financial Reports~~ 4. Sustainable Development

3

From Taiwan to the World

2000 Sinphar TPEx-listed 2002 Sinphar TWSE-listed 2014 SynCoreBio TPEx-listed

1977 2002 Established Sinphar Invested in Sinphar TianLi & Ilan, Taiwan He-Tian Tianli

Generic drugs, functional food, Hangzhou ( CN ), Xinjiang(CN ) cosmetics Generic, TCM, natural products

2012

Merged ZuniMed Biotech

Nantou, Taiwan Medical devices

1997 ~~Established CanCap~~ Vancouver, Canada Clinical control for New Drug of North America, raw material sourcing

2008

~~Co-found SynCoreBio~~ Ilan, Taiwan New Drug Development

==> picture [176 x 93] intentionally omitted <==

==> picture [106 x 93] intentionally omitted <==

==> picture [98 x 93] intentionally omitted <==

==> picture [102 x 93] intentionally omitted <==

==> picture [140 x 93] intentionally omitted <==

==> picture [100 x 93] intentionally omitted <==

4

Major Developments

Diverse Development of Generic Drugs

==> picture [273 x 274] intentionally omitted <==

Value-added New Drugs R&D Comprehensive Plans for Natural Plant Extracts

5

Integration of Resources

• Sinphar & SynCore • Joint R & D

• Improvement in manufacturing (Example: freeze-drying process)

• ~~Natural~~

• Sinphar & Tian ~~Li Medical~~ • Herbal Mutual benefit in Devices

• R&D achievement Extraction

• • Strategic cooperation for patented products

• (Example: obtained 4 health food permits)

Sinphar & ZuniMed ISO15378 Class 100,000 clean room

(Example: bottleware integration)

6

Stride Ahead Exporting to over 10 countries/regions and increasing.

According to TFDA as of 12/1 and DCB data:

1. API manufacturer:29

2. Western medicine manufacturer:144

3. Pharmaceutical/medicinal related companies: over 100

4. Medical device companies: over 10,000

==> picture [201 x 76] intentionally omitted <==

International Collaboration

Alliances

• Medical centers, hospitals and clinics

According to Ministry of Finance data, there are more than 10,500 pharmacies in Taiwan.

• 1,300 Sinphar Counters

• Drug stores/retail stores

• • Major e-commerce platforms

7

Talent Management

1. Hard assets: Bronze prize winning TTQS approved vocational training center

2. Intangible assets: utilize Talent Management System (TMS) to track and learning and professional development.

3. Since 2024, TMS recorded an average monthly use of 170.8 employees, monthly average log-in count is 532.7.

4. Main professional development:

Subject

Content

• Professional Training in areas of marketing, R&D, digital technology, Training management, quality regulation, manufacturing technology, electrical and mechanical, manufacturing equipment, …etc.

• PIC/S GMP Scheduled trained according to regulation. SOP & QCP Periodic SOP & QCP training according to responsibility and position.

==> picture [184 x 105] intentionally omitted <==

==> picture [184 x 94] intentionally omitted <==

==> picture [184 x 101] intentionally omitted <==

==> picture [184 x 94] intentionally omitted <==

Occupational Occupational safety, environmental safety, fire safety … etc. Safety

New hire/Foreign New hire training, language training, introduction to all subjects hire above.

8

==> picture [137 x 93] intentionally omitted <==

Comprehensive health promotion

==> picture [223 x 82] intentionally omitted <==

----- Start of picture text -----

Recovery
----- End of picture text -----

Drugs

New Product Released in 2024: 1

New Product Released in 2025: 2

==> picture [67 x 76] intentionally omitted <==

==> picture [66 x 76] intentionally omitted <==

==> picture [223 x 83] intentionally omitted <==

----- Start of picture text -----

Staying Healthy
----- End of picture text -----

Functional Supplements

==> picture [121 x 35] intentionally omitted <==

==> picture [222 x 83] intentionally omitted <==

----- Start of picture text -----

Youthfulness
----- End of picture text -----

Medical Cosmetology Products

New Product Released in 2024: 3 New Product Released in 2025: 4

New Product Released in 2024: 4 New Product Released in 2025: 10

9

==> picture [137 x 93] intentionally omitted <==

Comprehensive Product Line for All Ages

==> picture [330 x 381] intentionally omitted <==

==> picture [332 x 353] intentionally omitted <==

----- Start of picture text -----

Dermatology Ophthalmology Pediatrics
Oncology Otolaryngology Orthopedics
Obstetrics &
General Surgery Plastic Surgery
Gynecology
Metabolism Dental Gastroenterology
Urology General Medicine Psychiatry
----- End of picture text -----

Health Around the Corner

==> picture [80 x 88] intentionally omitted <==

==> picture [349 x 367] intentionally omitted <==

==> picture [81 x 101] intentionally omitted <==

==> picture [80 x 92] intentionally omitted <==

==> picture [80 x 98] intentionally omitted <==

==> picture [111 x 64] intentionally omitted <==

==> picture [111 x 65] intentionally omitted <==

==> picture [112 x 64] intentionally omitted <==

==> picture [111 x 64] intentionally omitted <==

==> picture [112 x 63] intentionally omitted <==

==> picture [85 x 107] intentionally omitted <==

==> picture [86 x 99] intentionally omitted <==

==> picture [86 x 94] intentionally omitted <==

==> picture [86 x 94] intentionally omitted <==

==> picture [112 x 64] intentionally omitted <==

Post Pandemic Care

==> picture [91 x 124] intentionally omitted <==

==> picture [94 x 120] intentionally omitted <==

==> picture [511 x 437] intentionally omitted <==

==> picture [93 x 134] intentionally omitted <==

==> picture [96 x 119] intentionally omitted <==

==> picture [93 x 122] intentionally omitted <==

==> picture [82 x 102] intentionally omitted <==

==> picture [101 x 124] intentionally omitted <==

==> picture [84 x 114] intentionally omitted <==

12

==> picture [83 x 45] intentionally omitted <==

International Award Winning Product

==> picture [718 x 330] intentionally omitted <==

==> picture [364 x 109] intentionally omitted <==

13

14

==> picture [115 x 73] intentionally omitted <==

==> picture [289 x 54] intentionally omitted <==

經107例人體試驗 證實有感提升 ~~保護~~ *文獻發表中

==> picture [163 x 153] intentionally omitted <==

==> picture [349 x 268] intentionally omitted <==

經國際學術發表文獻證實 、 具調節免疫 緩解過敏體質雙重作用

Health Foods for Aging Society

三高全照護健康食品系列

==> picture [351 x 195] intentionally omitted <==

==> picture [720 x 192] intentionally omitted <==

Sinphar Health Park – Sharing Knowledge with the Public

1. Since the opening of the Park, over 80,000 people have visited to understand the manufacturing process of pharmaceuticals and food products. An expansion plan is underway to accommodate the expected over 30,000 visitors for 2025

2. Located near Renshan Botanical Garden and Xinliao Waterfall, this scenic and freeadmission Park is an ideal place for tourists visiting Yilan to relax and learn more about heath and well-being

==> picture [165 x 101] intentionally omitted <==

==> picture [163 x 101] intentionally omitted <==

==> picture [152 x 87] intentionally omitted <==

==> picture [156 x 90] intentionally omitted <==

17

Production Digitalization

==> picture [716 x 462] intentionally omitted <==

----- Start of picture text -----

Shipping
Production Plan Scheduling
Warehouse
MRP Create Work BI Cockpit
Order
PO
Warehouse
Receiving
ISO/IEC 27001
IQC ISMS QA
Warehouse FQC
Warehouse Weighing
Packaging
Picking MM WIP Warehouse MP WIP Warehouse
IPQC Cockpit
ERP LIMS
Production Data
APS MES
PLC & Equipment & Sensor
WMS SCADA
18
----- End of picture text -----

International Markets

Japan

• Product G, launched in 2020, steady growth

Thailand

• Product T, applied in 2024, expect to launch in 2026

• Product G, obtained license in 2023

• Product C, launched 2023, steady growth

Malaysia

• Product T, laun ~~ched in 2020, steady~~ growth

• Product S, launched in 2022, steady growth

• Product K, launched in 2021 2021, steady growth

Indonesia

Philippines

• Product L, applied in 2022, expect to launch in 2024

• Product G, obtained license in 2023

• Vietnam

• Product G, expect to obtain license in 2025

• Product A, applied in 2022, expect to launch in 2026

• ~~Product L, applied in 2022~~

• • Product C, launched in 2023, steady growth

Iraq

• Product A, applied in 2022

• Product L, applied in 2022

• Product G, applied in 2022

• Product B, launched in 2023, steady growth

19

Sustainability

Energy Saving

Energy Intensity* Continues to Decrease (2023 vs 2021) ~~17.3%~~

(Purchased electricity + liquefied petroleum gas + diesel = gigajoules/revenue in millions NTD)

==> picture [92 x 66] intentionally omitted <==

Carbon Reduction Emission Intensity* Continues to Decrease ~~(2023 vs 2021)~~ 17.0%

Emission from Scope 1 + Scope 2 = Metric ton of Co2e/revenue in millions NTD

20

Growth

Therapeutic Drugs

==> picture [148 x 74] intentionally omitted <==

• New listing expected in 2025: 1 (Mild eczema and seborrheic dermatitis)

• Co-develop and manufacture with Japanese pharmaceutical companies and expand ASEAN market

• Agent to Japanese products for domestic market

• API in-depth development plan (Sulfamethoxazole and Mesulphen obtained license; 4 more in development)

• Establish domestic alliance

Functional Supplements

• 4 New listings are expected in 2025 (male health, Blood sugar regulation, intestinal health, throat health)

Cancer Tre ~~atment Injectable/Solid Dosage Form~~

• Expand the R&D and manufacturing capacity of cancer injectables

• Manufacture cytotoxic injectables with fully automated isolator and setup closed system solid dosage form

• MST launched in 2021; in 2023 added new indication

• Megestrol launched in 2022

Sinphar Health Park

• Co-develop with local government to setup a regional tourist attraction route

21

Management Philosophy 580,000

==> picture [215 x 144] intentionally omitted <==

575,000

570,000 565,000

560,000 555,000

550,000 111 年前三季 112 年前三季 113 年前三季 (*內含員工薪資、勞健 ~~保、退休金及其他用人費用)~~

==> picture [251 x 170] intentionally omitted <==

112年杏輝宜蘭馬拉松

蘭陽媽祖文化節

贊助失智症照護協會

==> picture [179 x 90] intentionally omitted <==

捐贈宜蘭縣政府防疫物資

連續九年杏輝生技營

贊助杏輝宜蘭馬拉松

==> picture [173 x 103] intentionally omitted <==

與縣政府共同推廣搶孤

==> picture [173 x 90] intentionally omitted <==

112年頭城、台南搶孤冠軍

==> picture [174 x 94] intentionally omitted <==

優良食品製造業者楷模 22

Pipeline

==> picture [105 x 22] intentionally omitted <==

==> picture [709 x 417] intentionally omitted <==

----- Start of picture text -----

6
3
----- End of picture text -----

Sinphar Group's New Drug Catalog

Refer to Annual Report from Sinphar and SynCore for more details

Memoregain® SB03 Veregen TLCT Plus EGW Vascular dementia Launched in 20 Obtained license countries Sold for RMB55,000,000

SB05 PC Pancreatic Cancer Second Line Treatment:Clinical trial Phase Ⅲ First Line Treatment: NMPA approved; Phase Ⅲ clinical trial

ST01 ST02 Alzheimer's disease Chronic stable angina US/TW FDA approved US/TW FDA approved Clinical phase Ⅱ Clinical phase Ⅱ TW Health Food License Completed SB02 SB01 Cancer drug Head and neck cancer Pre-clinical formulation Clinical phase Ⅱ development

SF01 Cancer adjuvant therapy ~~Pre-clinical research~~ completed TW Health Food License

SB04 Dry age-related macular degeneration Clinical phase Ⅱ / Ⅲ

GF159 Brain health food Healthy people clinical trials completed SB05 TNBC Triple negative breast cancer Clinical phase Ⅲ

24

天然資源（原料/提取物）

==> picture [181 x 148] intentionally omitted <==

==> picture [176 x 149] intentionally omitted <==

==> picture [164 x 148] intentionally omitted <==

==> picture [148 x 148] intentionally omitted <==

Memoregain® TLCT Plus 天力再生 ® 管花肉蓯蓉提取物 ( Cistanche tubulosa extract)

Lipucan[® ] 天力速康 [® ] ~~茯苓三萜菁萃物~~ (Poria cocos triterpenoids)

Protygold[® ] KAZINAKE 杏补宜 [® ] 杏补宜 [® ] ~~核桃肽 初榨核桃油~~ (Walnut oligopeptide) (Walnut Oil)

KAZINAKE[® ]

==> picture [125 x 49] intentionally omitted <==

==> picture [67 x 46] intentionally omitted <==

Organic certification

==> picture [99 x 46] intentionally omitted <==

、 、 EU Ecocert USDA Organic China Organic Food Certification Center

RD research achievements

Walnut oil won the ITQI and Monde Selection awards in 2023

==> picture [61 x 66] intentionally omitted <==

==> picture [209 x 235] intentionally omitted <==

The ingredient has been sold to 14 countries.

==> picture [71 x 71] intentionally omitted <==

Walnut oligopeptide won 4 gold and 1 silver international patent invention awards in 2022

==> picture [52 x 66] intentionally omitted <==

Walnut oligopeptide obtains Nutritional Intelligence_ New Plant Power Award in 2023

SCI papers patents in countries

Differentiated Marketing

Market

• Major markets in Taiwan and China as food raw material; begin to export in 2024 now sold to 14 countries around the world, with focus on northeast Asian and ASEAN countreis

• Looking for new markets post COVID-19 pandemic

Marketing

• Provide specialized customer support with R&D and technical advantage and comprehensive supply chain

• • Provide locally approved raw materials

==> picture [145 x 109] intentionally omitted <==

Comprehensive supply chain Quality

Publish patent and research findings

Scientific Safety Research

Toxicity and contamination tests

27

Revenue Overview for the

Unit ： NTD in thousands

Same Period in Recent Years

==> picture [671 x 263] intentionally omitted <==

----- Start of picture text -----

2,500,000 40.0%
2,296,239
2,214,367
2,094,144
2,000,000
39.0% 39.0%
38.7%
1,500,000
38.0%
1,000,000
37.0%
500,000
36.5%
0 36.0%
111 年前三季 112 年前三季 113 年前三季
療效用藥 功能性食品 其他 合計 毛利率
----- End of picture text -----

1. As of November 2024, cumulative sales revenue is NTD 2.859 billion, which is NTD 140 million more 。

for the same period last year.

1. Product combination and batch change have increased net profit. This year sees the beginning of sales in the USA. This year's shipments have reached nearly 30% more than the first three quarters of 2022.

28

Unit: NTD in Thousands

Cash Flow

==> picture [256 x 57] intentionally omitted <==

Net Cash generated by operating activities Net Cash used in investing activities

Acquisition of property, plant and equipment

Prepaid equipme ~~nt~~

Net Cash generated by financing activities Cash and cash equivalents, end of the period

Sinphar Group Sinphar Group Sinphar Group Q1~Q3 2024 2023 Q1~Q3 2023

405,341 296,370

155,564 -250,019 -131,982 ~~-82~~ ,809 -149,294 995,134

-300,957 -334,563 -137,646 -198,725 ~~-58,703 -96,785~~ -128,553 -120,671 1,061,935 1,074,489

-128,553 1,061,935

Continue to invest. Will commence building intelligent warehouse and health center.

29

Unit: NTD in Thousands

Ratio

==> picture [296 x 61] intentionally omitted <==

Sinphar Group Sinphar Group Q1~Q3 2024 Q1~Q3 2023

Debt Ratio (%) Current Ratio (%)

44.6 47.0

227.0

207.7

Accounts Receivable Turnover Accounts Payable Turnover Inventor Turnover y

==> picture [259 x 60] intentionally omitted <==

5.12

4.43 6.23

7.52

2.31

2.41

Sinphar Group SynCore Q3 2024 Q3 2024

Cash and cash equivalents, end of the period Unspent bank financing

1,061,935

1,000,000

210,880 360,000

30

Sustainability

==> picture [618 x 348] intentionally omitted <==

----- Start of picture text -----

Risk Corporate
Honesty
Management Management
Global Talent recruit and Customer
warming maintenance health
Ene rgy Occupational Supply chain
management safety and health management
Social Innovation and
Environmental
Responsibility R&D
----- End of picture text -----

31

Corporate Social Responsibility

1. Host health forum, biotechnology camp. Create a platform to facilitate and cultivate the interaction of medical, academic, and biotechnology professionals

2. Continue to be a sponsor for Breast Cancer Foundation, Spinal Cord Injury Foundation, The Diabetes Association of the Republic of China (Taiwan), Taiwan Yilan Association of Diabetes Supporters, and Youngsun Culture & Education Foundation

3. Donate to the National Health Service and the Taiwan Cancer Foundation for new drug development and Medicaid

4. Co-found an “R&D Center for Age-related Macular Degeneration” with National Taiwan University Hospital, for early diagnosis and early detection of age-related macular degeneration

5. Long-term spon ~~sor of the street lights in Wanshan Village, Zhongshan Village and Rens~~ han Trail. A sponsor for tourist information center in Dongshan County

6. Sponsor nutritional supplements and vegetables to hospitals and medical personnel in Yilan County

7. Sponsored in remote villages, free clinics by Luodong Boai Hospital and co-sponsored with Taipei Zhongxiao Rotary Club breast cancer screenings

8. Sponsor Oxaliplatin to the National Institutes of Health to conduct an IIT trial for pancreatic cancer

9. Donate to Yilan County Dementia Care Service Association

32

Corporate Social Responsibility Supports Education and Sports

1. Donate NTD 5 million over 5 years to Kaohsiung Medical University for students in need of financial assistance

2. Sinphar Group and Yilan County Government will jointly organize annual “Sinphar Yilan Marathon” for 3 years with a sponsorship of NTD 8 million. The Company announced that the sponsorship would be extended for another 5 years.

3. Sponsor financial aid program to students in need of financial assistance from National Taiwan University, Faculty of Pharmacy and offer internship opportunities

4. Provide internship for students from Kaohsiung Medical University, Taipei Medical University, National Defense Medical Center, China Medical University and Chia Nan University of Pharmacy & Science. Also provide scholarship for Kaohsiung Medical University and National Defense Medical Center

5. Sponsor Yilan High School football team, Shunan Junior High School baseball team and the facilities for elementary schools in Dongshan Township for 4 years.

6. Set up a “Chiang Ku” Cultural Park, and signed a MOU with Yilan County to promote “Chiang Ku”

7. From 2020 to 2022 sponsored the Outstanding Award for Taitung Geng Yuan Cup Junior Baseball League

33

企業社會公益

==> picture [720 x 420] intentionally omitted <==

34

==> picture [720 x 341] intentionally omitted <==

==> picture [113 x 113] intentionally omitted <==

Q & A

35